Immodulon, the immuno-oncology company, announces that their IMM-101-015 Phase II clinical trial has commenced. The open-label clinical study will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an immune checkpoint inhibitor, in 26 patients with unresectable stage III or stage IV melanoma who are either treatment-naïve (cohort A) or those whose disease has progressed during treatment with anti-PD-1 checkpoint inhibitor drugs (cohort B).

18 patients will be enrolled into cohort A and eight patients into cohort B. Ipilimumab may be used as a subsequent treatment in place of Nivolumab alongside IMM-101 for patients in cohort B if their disease continues to progress whilst on study.

Further information available on: the Clinical Trials .Gov website (